Clinician‐reported signs of eczema: IGA (number with cleared or marked improvement); short term (earliest time point within 1‐4 weeks) · children and adults with mild to severe eczema
Potent probably leads to higher clinician‐reported signs of eczema: IGA (number with cleared or… compared with mild‐potency topical corticosteroid (moderate certainty).
1 finding from 1 review
Patient‐reported symptoms of eczema · children and adults with mild to severe eczema
1 finding from 1 review
Local adverse events: skin thinning; end of treatment (16‐20 weeks + 2‐4 weeks acute phase) · children and adults with mild to severe eczema
1 finding from 1 review
Systemic adverse events: abnormal cortisol; end of treatment (1‐6 weeks) · children and adults with mild to severe eczema
1 finding from 1 review
Clinician‐reported signs of eczema: IGA (number with cleared or marked improvement); short term (earliest time point within 1‐4 weeks) · children and adults, most with moderate to severe eczema
Potent showed no clear difference in clinician‐reported signs of eczema: IGA (number with cleared or… compared with moderate‐potency topical corticosteroid (moderate certainty).
1 finding from 1 review
Eczema diagnosis by 1 to 3 years · infants
Skin care intervention showed no clear difference in eczema diagnosis by 1 to 3 years compared with standard skin care or no skin care intervention (moderate certainty).
1 finding from 1 review
IgE‐mediated food allergy (oral food challenge) by 1 to 3 years · infants
Skin care intervention showed no clear difference in igE‐mediated food allergy (oral food challenge) by 1 to 3 years compared with standard skin care or no skin care intervention (low certainty).
1 finding from 1 review
Slippages (over the intervention period) · infants
Skin care intervention showed no clear difference in slippages (over the intervention period) compared with standard skin care or no skin care intervention (low certainty).
1 finding from 1 review
Skin infection (over the intervention period) · infants
Skin care intervention probably leads to higher skin infection (over the intervention period) compared with standard skin care or no skin care intervention (moderate certainty).
1 finding from 1 review
Stinging/allergic reactions to moisturisers (over the intervention period) · infants
Skin care intervention showed no clear difference in stinging/allergic reactions to moisturisers (over the intervention… compared with standard skin care or no skin care intervention (low certainty).
1 finding from 1 review
Time to onset of eczema · infants
Skin care intervention showed no clear difference in time to onset of eczema compared with standard skin care or no skin care intervention (moderate certainty).
1 finding from 1 review
Parent report of immediate reaction to common food allergen (at 2 years) · infants
Skin care intervention showed no clear difference in parent report of immediate reaction to common food allergen (at 2… compared with standard skin care or no skin care intervention (low certainty).
1 finding from 1 review
Allergic sensitisation to a food allergen (at 1 to 3 years) · infants
Skin care intervention showed no clear difference in allergic sensitisation to a food allergen (at 1 to 3 years) compared with standard skin care or no skin care intervention (low certainty).
1 finding from 1 review
Primary outcome: complete clinical response (malar/discoid rash) · patients with cutaneous disease in systemic lupus erythematosus
Oral methotrexate may leads to higher primary outcome: complete clinical response (malar/discoid rash) compared with placebo (low certainty).
1 finding from 1 review
Secondary outcome: clinical flare · patients with cutaneous disease in systemic lupus erythematosus
Oral hydroxychloroquine probably leads to lower secondary outcome: clinical flare compared with placebo (moderate certainty).
1 finding from 1 review
Secondary outcome: CLASI · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Secondary outcome: Dermatology Quality of Life measure · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus
Oral hydroxychloroquine showed no clear difference in adverse events: severe compared with placebo (moderate certainty).
1 finding from 1 review
Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus
Oral hydroxychloroquine showed no clear difference in adverse events: minor compared with placebo (moderate certainty).
1 finding from 1 review
Complete response · patients with cutaneous disease in systemic lupus erythematosus
Oral dehydroepiandrosterone showed no clear difference in primary outcome: complete clinical response compared with placebo (moderate certainty).
1 finding from 1 review